UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study

The Lancet (British edition), 2013-06, Vol.381 (9883), p.2091-2099

2013

Volltextzugriff (PDF)

Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates

Antimicrobial Agents and Chemotherapy, 2005-08, Vol.49 (8), p.3264-3273

2005

Volltextzugriff (PDF)

Safety and efficacy of raltegravir in patients with HIV‐1 and hepatitis B and/or C virus coinfection

HIV medicine, 2012-02, Vol.13 (2), p.127-131

2012

Volltextzugriff (PDF)

Safety and tolerability of ertapenem

Journal of antimicrobial chemotherapy, 2004-06, Vol.53 (suppl-2), p.ii75-ii81

2004

Volltextzugriff (PDF)

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses

Journal of acquired immune deficiency syndromes (1999), 2010-09, Vol.55 (1), p.39-48

2010

Volltextzugriff (PDF)

Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals

Journal of acquired immune deficiency syndromes (1999), 2006-12, Vol.43 (5), p.509-515

2006

Volltextzugriff (PDF)

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

Journal of acquired immune deficiency syndromes (1999), 2007-10, Vol.46 (2), p.125-133

2007

Volltextzugriff (PDF)

Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia

The New England journal of medicine, 2004-09, Vol.351 (14), p.1391-1402

2004

Volltextzugriff (PDF)

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

AIDS (London), 2007-11, Vol.21 (17), p.2315-2321

2007

Volltextzugriff (PDF)

Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection

Journal of acquired immune deficiency syndromes (1999), 2009-11, Vol.52 (3), p.350-356

2009

Volltextzugriff (PDF)

Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study

Transplant infectious disease, 2006-03, Vol.8 (1), p.31-37

2006

Volltextzugriff (PDF)

In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART)

Journal of antimicrobial chemotherapy, 2005-06, Vol.55 (6), p.965-973

2005

Volltextzugriff (PDF)

Effects of Omeprazole on Plasma Levels of Raltegravir

Clinical infectious diseases, 2009-02, Vol.48 (4), p.489-492

2009

Volltextzugriff (PDF)

Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies

AIDS (London), 2011-07, Vol.25 (11), p.1365-1369

2011

Volltextzugriff (PDF)

Management of Complicated Appendicitis and Comparison of Outcome with Other Primary Sites of Intra-abdominal Infection: Results of a Trial Comparing Ertapenem and Piperacillin-Tazobactam

Journal of chemotherapy (Florence), 2004-02, Vol.16 (1), p.62-69

2004

Volltextzugriff (PDF)

Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients

Cancer, 2006-01, Vol.106 (2), p.466-473

2006

Volltextzugriff (PDF)

Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age

Journal of the Pediatric Infectious Diseases Society, 2015-12, Vol.4 (4), p.e76-e83

2015

Volltextzugriff (PDF)

Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial

Antiviral therapy, 2018, Vol.23 (1), p.21-32

2018

Volltextzugriff (PDF)

Acquisition of Resistant Bowel Flora during a Double-Blind Randomized Clinical Trial of Ertapenem versus Piperacillin-Tazobactam Therapy for Intraabdominal Infections

Antimicrobial Agents and Chemotherapy, 2005-08, Vol.49 (8), p.3217-3221

2005

Volltextzugriff (PDF)

During HIV‐1 infection most blood dendritic cells are not productively infected and can induce allogeneic CD4+ T cells clonal expansion

Clinical and experimental immunology, 1992-05, Vol.88 (2), p.226-236

1992

Volltextzugriff (PDF)

Comparative In-Vitro Activities of Ertapenem against Aerobic Bacterial Pathogens Isolated from Patients with Complicated Intra-abdominal Infections

Journal of chemotherapy (Florence), 2002-06, Vol.14 (3), p.227-233

2002

Volltextzugriff (PDF)

Doravirine (MK-1439): a novel HIV-1 NNRTI with a distinct resistance profile

Antiviral therapy, 2014-01, Vol.19, p.A125-A125

2014

Volltextzugriff (PDF)

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

Journal of Virology, 1996-12, Vol.70 (12), p.8270-8276

1996

Volltextzugriff (PDF)

Safety and efficacy of raltegravir in patients co‐infected with HIV and hepatitis B and/or C virus: complete data from Phase III double‐blind studies

Journal of the International AIDS Society, 2012-11, Vol.15 (S4), p.1-2

2012

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(54)

Sprache

Englisch
(54)

Erscheinungsjahr

n.n

Thema

Science & Technology
(46)
Humans
(44)
Life Sciences & Biomedicine
(44)
Infectious Diseases
(36)
Male
(32)
Female
(30)
Adult
(29)
Biological And Medical Sciences
(28)
Medical Sciences
(28)
Hiv Infections - Drug Therapy
(26)
Immunology
(22)
Middle Aged
(22)
Aids/hiv
(18)
Double-Blind Method
(18)
Human Immunodeficiency Virus
(18)
Treatment Outcome
(18)
Hiv
(17)
Microbiology
(17)
Pharmacology. Drug Treatments
(17)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(16)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates

Safety and efficacy of raltegravir in patients with HIV‐1 and hepatitis B and/or C virus coinfection

Safety and tolerability of ertapenem

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses

Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials

Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection

Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study

In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART)

Effects of Omeprazole on Plasma Levels of Raltegravir

Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies

Management of Complicated Appendicitis and Comparison of Outcome with Other Primary Sites of Intra-abdominal Infection: Results of a Trial Comparing Ertapenem and Piperacillin-Tazobactam

Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients

Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age

Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial

Acquisition of Resistant Bowel Flora during a Double-Blind Randomized Clinical Trial of Ertapenem versus Piperacillin-Tazobactam Therapy for Intraabdominal Infections

During HIV‐1 infection most blood dendritic cells are not productively infected and can induce allogeneic CD4+ T cells clonal expansion

Comparative In-Vitro Activities of Ertapenem against Aerobic Bacterial Pathogens Isolated from Patients with Complicated Intra-abdominal Infections

Doravirine (MK-1439): a novel HIV-1 NNRTI with a distinct resistance profile

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

Safety and efficacy of raltegravir in patients co‐infected with HIV and hepatitis B and/or C virus: complete data from Phase III double‐blind studies

Suchergebnisse filtern